文献速递银屑病与炎症性皮肤病

银屑病生物制剂对生活质量改善的比较效果

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.
PubMed 文献 · Br J Dermatol · 2017-10-19

该前瞻性队列研究纳入2152例银屑病患者,比较阿达木单抗、依那西普和乌司奴单抗对健康相关生活质量的改善效果。结果显示生物制剂治疗显著改善DLQI和EQ-5D,且依那西普相比阿达木单抗达到DLQI 0/1的可能性更低。

要点

  • 生物制剂治疗6个月和12个月时DLQI和EQ-5D均显著改善
  • 依那西普相比阿达木单抗达到DLQI 0/1的可能性更低
  • 女性、多种合并症、吸烟及基线HRQoL较差预测改善可能性低

核心结论

  • 常规临床实践中生物制剂治疗显著改善银屑病患者健康相关生活质量。
  • HRQoL改善受生物制剂选择、基线HRQoL损害、生活方式特征和合并症影响。

研究设计与样本

  • 前瞻性队列研究,纳入2152例银屑病患者,其中阿达木单抗1239例、依那西普517例、乌司奴单抗396例,81%为生物制剂初治。
  • 在6个月和12个月时使用DLQI和EQ-5D评估HRQoL变化,采用多变量回归模型识别与达到DLQI 0/1及EQ-5D效用评分改善相关的因素。

主要发现

  • 全队列中位(四分位距)DLQI从基线18(13-24)改善至6个月时2(0-7),EQ-5D从0·73(0·69-0·80)改善至0·85(0·69-1·00),P < 0·001。
  • 12个月时获得相似改善。
  • 12个月时多变量回归显示女性、多种合并症、吸烟及基线DLQI较高或EQ-5D效用评分较低预测达到DLQI 0/1或EQ-5D改善的可能性更低。
  • 相比阿达木单抗,接受依那西普(而非乌司奴单抗)的患者达到DLQI 0/1的可能性更低。
  • 生物制剂之间在EQ-5D改善方面无显著差异。

临床怎么用

  • 生物制剂可显著改善银屑病患者HRQoL,选择生物制剂时应考虑其对HRQoL的改善效果。
  • 对于女性、多种合并症、吸烟或基线HRQoL较差的患者,应预期HRQoL改善可能性较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence of the comparative effectiveness of biological therapies for psoriasis on health-related quality of life (HRQoL) in routine clinical practice is limited. OBJECTIVES: To examine the comparative effectiveness of adalimumab, etanercept and ustekinumab on HRQoL in patients with psoriasis, and to identify potential predictors for improved HRQoL. METHODS: This was a prospective cohort study in which changes in HRQoL were assessed using the Dermatology Life Quality Index (DLQI) and EuroQoL-5D (EQ-5D) at 6 and 12 months. Multivariable regression models were developed to identify factors associated with achieving a DLQI of 0/1 and improvements in the EQ-5D utility score. RESULTS: In total, 2152 patients with psoriasis were included, with 1239 patients on adalimumab, 517 on etanercept and 396 on ustekinumab; 81% were biologic naïve. For the entire cohort, the median (interquartile range) DLQI and EQ-5D improved from 18 (13-24) and 0·73 (0·69-0·80) at baseline to 2 (0-7) and 0·85 (0·69-1·00) at 6 months, respectively (P < 0·001). Similar improvements were achieved at 12 months. At 12 months, multivariable regression modelling showed that female sex, multiple comorbidities, smoking and a higher DLQI or a lower EQ-5D utility score at baseline predicted a lower likelihood of achieving a DLQI of 0/1 or improvement in the EQ-5D. Compared with adalimumab, patients receiving etanercept, but not ustekinumab, were less likely to achieve a DLQI of 0/1. There was no significant difference between the biological therapies in EQ-5D improvement. CONCLUSIONS: In routine clinical practice biological therapies produce marked improvement in HRQoL, which is influenced by the choice of biological therapy, baseline impairment in HRQoL, lifestyle characteristics and comorbidities. These findings should help inform selection of optimal biological therapy for patients related to improvements in HRQoL.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Iskandar IYK, Ashcroft DM, Warren RB, et al. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol. 2017. PMID: 28369707. doi:10.1111/bjd.15531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。